Mammoth Biosciences disclosed non-human primate data for its lead in vivo gene editing program that aims to permanently lower triglycerides. The company presented monkey efficacy and safety results supporting progression to a first-in-human study, marking a notable step for a firm co-founded by CRISPR pioneer Jennifer Doudna. Mammoth’s approach leverages proprietary editing chemistry and in vivo delivery to edit hepatic targets linked to lipid metabolism. The data signal advancing capability in liver-directed gene editing and add to the competitive landscape of single-dose genetic cardiovascular interventions. Mammoth’s move will be watched for on-target durability, safety signals related to off-target editing, and translatability of triglyceride lowering to clinical cardiovascular outcomes.